<?xml version="1.0" encoding="utf-8"?>
<recommendedContent xmlns="http://api.mspoke.com">
    <recommendedItem id="20100101_19_404"
                     title="Tailor Etanercept to Symptoms in Psoriasis and Psoriatic Arthritis (CME/CE)"
                     score="0.011"
                     href="http://www.medpagetoday.com/Rheumatology/Arthritis/tb/18309?impressionId=1265790496985"
                     
      &lt;p&gt;The decision to use once-weekly or twice-weekly etanercept (Enbrel) in patients with both psoriasis and psoriatic arthritis should be determined by the cutaneous and joint symptoms of the patient, researchers said.&lt;/p&gt;
&lt;p&gt;In a blinded, multicenter study, 46% of patients who received the drug twice a week had cleared or almost cleared their skin manifestations of psoriasis at week 12, compared with 32% of those who received the drug only once each week (&lt;em&gt;P&lt;/em&gt;&amp;lt;0.001), according to Wolfram Sterry, MD, of Charite University Medicine in Berlin, and colleagues.&lt;/p&gt;
&lt;p&gt;In contrast, there were no differences in response for arthritis symptoms, with 77% of those in the twice-weekly group and 76% of those in the once-weekly group meeting predetermined psoriatic arthritis response criteria at week 12, the researchers reported online in the &lt;em&gt;BMJ&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;An estimated 30% of patients with psoriasis have an arthritic component to their disease, manifesting as chronic inflammation of the joints and entheses.&lt;/p&gt;
&lt;p&gt;&quot;The challenge of treating patients with both active psoriasis and active psoriatic arthritis is to optimize the treatment of both disease manifestations to give the best overall outcome,&quot; the investigators wrote.&lt;/p&gt;
&lt;p&gt;Etanercept, a fully human tumor necrosis factor (TNF) inhibitor, is approved for use in both conditions based on findings showing that TNF and other cytokines are upregulated in both inflamed joint and skin tissues.&lt;/p&gt;
&lt;p&gt;To determine the efficacy of two different treatment regimens in patients who had not previously received a TNF inhibitor but had moderate-to-severe skin symptoms and active arthritis, Sterry and colleagues recruited 752 patients from 98 centers for PRESTA (Psoriasis Randomized Etanercept STudy in subjects with psoriatic Arthritis).&lt;/p&gt;
&lt;p&gt;They paired rheumatologists and dermatologists to cooperatively assess effects of the drug.&lt;/p&gt;
&lt;p&gt;Patients were randomized to receive subcutaneous etanercept, 50 mg once or twice weekly for 12 weeks, and for an additional 12 weeks both groups received 50 mg once weekly.&lt;/p&gt;
&lt;p&gt;To maintain blinding, the once-weekly group also received a placebo injection during the first 12 weeks.&lt;/p&gt;
&lt;p&gt;Participants&apos; mean age was 46.5 years. Mean duration of psoriasis was 18.9 years, and mean duration of arthritis was seven years. Most were white men.&lt;/p&gt;
&lt;p&gt;For the joint symptoms, the proportions of patients who achieved American College of Rheumatology (ACR) responses were similar at weeks 12 and 24 in the two groups.&lt;/p&gt;
&lt;p&gt;At week 12, 66.4% and 60.8% of patients in the twice- and once-weekly groups, respectively, had achieved ACR20 responses (representing a 20% improvement). At week 24, the corresponding proportions were 69% and 71.7%.&lt;/p&gt;
&lt;p&gt;At week 12, the percentage reductions in physician&apos;s global assessment of arthritis were 60% and 62% for the twice- and once-weekly groups (&lt;em&gt;P&lt;/em&gt;=0.823), and at week 24 the corresponding percentages were 73% and 74% (&lt;em&gt;P&lt;/em&gt;=0.760).&lt;/p&gt;
&lt;p&gt;At baseline, enthesitis was found in 287 patients and dactylitis in 318. These two symptoms decreased comparatively in both groups at weeks 12 and 24.&lt;/p&gt;
&lt;p&gt;Skin findings included the following for the twice-weekly and once-weekly groups, respectively: &lt;ul&gt; &lt;li&gt;Improvement in physician&apos;s global assessment at week 12, 52% versus 45%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001&lt;/li&gt; &lt;li&gt;At week 24, 57% versus 55%, &lt;em&gt;P&lt;/em&gt;=0.420&lt;/li&gt; &lt;li&gt;Improvement in psoriasis area and severity index at week 12, 71% versus 62%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001&lt;/li&gt; &lt;li&gt;At week 24, 78% versus 74%, &lt;em&gt;P&lt;/em&gt;=0.110&lt;/li&gt; &lt;li&gt;75% improvement in psoriasis area and severity index at week 12, 55% versus 36%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.001&lt;/li&gt; &lt;li&gt;At week 24, 70% versus 62%, &lt;em&gt;P&lt;/em&gt;&amp;lt;0.026&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Clearly there were differences in the optimal dosages for the skin lesions at week 12, but when the dosage was decreased to once weekly for the two groups, improvements in both joint and skin symptoms continued to improve, and at week 24 the responses were similar in the two groups, the investigators observed.&lt;/p&gt;
&lt;p&gt;&quot;We found that initial treatment of the psoriasis with etanercept 50 mg twice weekly may allow for more rapid clearance of skin lesions than a 50 mg weekly regimen,&quot; they wrote, noting that the higher dose therefore may be preferable for patients with more severe cutaneous involvement.&lt;/p&gt;
&lt;p&gt;In contrast, at no time was the twice-weekly regimen more effective in treating the articular symptoms, so 50 mg once weekly is a sufficient dose for the treatment of joint symptoms alone, they concluded.&lt;/p&gt;
&lt;p&gt;There were no differences in safety between the regimens.&lt;/p&gt;
&lt;p&gt;It is not clear why the higher dose cleared the skin symptoms more rapidly than the low dose but did not have an additional benefit for the joint symptoms.&lt;/p&gt;
&lt;p&gt;&quot;These two different organ systems may have dissimilar autoimmune inflammatory environments, allowing for differences in local concentrations of tumor necrosis factor or in disease burdens or a subtle difference in tissue penetration of drug, although little information is available to support any particular mechanism,&quot; the researchers noted.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;Wyeth Research, which was acquired by Pfizer in October 2009, sponsored the trial.&lt;/p&gt;&lt;p&gt;Authors and sponsor were involved in study design, interpretation of data, manuscript preparation, and decision to publish.&lt;/p&gt;&lt;p&gt;Statistical analyses were done by the biostatistics department of Wyeth Research.&lt;/p&gt;&lt;p&gt;Several co-authors are employees of Pfizer, and others have received fees from multiple pharmaceutical companies including Wyeth.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_190"
                     title="Rising Costs -- the Real Heartbreak of Psoriasis (CME/CE)"
                     score="-0.004"
                     href="http://www.medpagetoday.com/Dermatology/Psoriasis/tb/18028?impressionId=1265790496985"
                     
      &lt;p&gt;The heartbreak of psoriasis used to be the disease itself. Now it&apos;s the skyrocketing cost of treatment.&lt;/p&gt;
&lt;p&gt;From 2000 through 2008, the cost of brand-name drugs increased 66% on average, according to Vivianne Beyer, MD, and Stephen Wolverton, MD, of the Indiana University School of Medicine in Indianapolis (Beyer is currently at St. Vincent Hospital in Indianapolis).&lt;/p&gt;
&lt;p&gt;The cost of several of the drugs &quot;greatly outpaced&quot; both general inflation and the overall increase in cost of prescription medicines, the researchers reported in the January issue of &lt;em&gt;Archives of Dermatology.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;The disease, a chronic autoimmune illness, affects between 4.5 million and 7.5 million people in the U.S., the researchers noted.&lt;/p&gt;
&lt;p&gt;Up to a third of those do not respond to topical therapy. However, more effective systemic treatments appear to be underused, they said  --  perhaps in part because of cost, a major issue with newer biologic drugs.&lt;/p&gt;
&lt;p&gt;Analysis showed that current annual costs ranged from $1,197 for methotrexate (Rheumatrex, Trexall), at 7.5 milligrams a week, to $27,577 for two 12-week courses of alefacept (Amevive).&lt;/p&gt;
&lt;p&gt;Phototherapy costs ranged from $3,083 for a year of UV-B therapy to $7,288 annually for psoralen-UV-A treatment, including induction and maintenance.&lt;/p&gt;
&lt;p&gt;Acitretin (Soriatane) at 25 milligrams a day cost $9,163, comparable to the $9,999 for 400 milligrams daily of cyclosporine. But some patients need twice the dose of acitretin, which increases the annual cost to $17,613, the researchers said.&lt;/p&gt;
&lt;p&gt;The annual costs of the biologics used to treat psoriasis ranged from $18,384 to $27,577, but those requiring a loading dose  --  such as adalimumab (Humira) and infliximab (Remicade)  --  were more costly during the first year of treatment than in following years, they said.&lt;/p&gt;
&lt;p&gt;To obtain information about trends, the researchers compared year-over-year average wholesale prices for the various treatments.&lt;/p&gt;
&lt;p&gt;They found that percentage changes in drug prices between 2000 and 2008 ranged from a drop of 24.1% for methotrexate to an increase of 316% for the brand-name version of methoxsalen  --  Oxsoralen-Ultra.&lt;/p&gt;
&lt;p&gt;The second-largest increase was 157.5% for acitretin, they said.&lt;/p&gt;
&lt;p&gt;The biologics also increased in price, but not all were available for the entire period. For example, the cost of efalizumab (Raptiva) increased by 35.1% over a four-year period, while adalimumab&apos;s cost increased by 27.2% during a five-year interval, the researchers said.&lt;/p&gt;
&lt;p&gt;On average the increase was 66%, they said, which is markedly higher than inflation. Over the same period, the consumer price index-urban for all items rose 25.8%, and 30.1% for prescription drugs.&lt;/p&gt;
&lt;p&gt;The researchers did not include indirect costs, such as time away from work, direct costs such as inpatient care, or costs that arose because of adverse effects.&lt;/p&gt;
&lt;p&gt;One clinical implication of the findings is that physicians should consider cost as well as efficacy and tolerability when prescribing drugs for psoriasis, the researchers concluded.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The researchers did not report external support for the study. Wolverton reported financial links with Eli Lilly and Amgen.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20090101_19_450"
                     title="SDEF: Draft Guideline to Ease Methotrexate Liver Biopsy Recommendation"
                     score="-0.005"
                     href="http://www.medpagetoday.com/MeetingCoverage/SDEF/tb/12846?impressionId=1265790496985"
                     
      WAILEA, Hawaii, Feb. 12 -- The American Academy of Dermatology is poised to loosen the decade-old guideline recommendation aimed at reducing liver damage from giving methotrexate for psoriasis.
              &lt;br&gt; 
              &lt;br&gt;John Y.M. Koo, M.D., vice chairman of dermatology at the University of California San Francisco, said that he and other members of the AAD guidelines committee have &quot;hashed out in a manuscript form&quot; an update that recommends periodic liver biopsies when patients reach a threshold of 3.5 g of methotrexate.
              &lt;br&gt; 
              &lt;br&gt;That recommendation, Dr. Koo said during a presentation at the Skin Disease Education Foundation (SDEF) Hawaii Dermatology Seminar, would cover only patients &quot;who have no risk factors whatever -- no fatty liver disease, no obesity, no diabetes.&quot;
              &lt;br&gt; 
              &lt;br&gt;Patients with such risk factors are not recommended for methotrexate therapy. 
              &lt;p&gt; 
              &lt;p&gt;Dr. Koo said the guideline must be approved by the AAD, but he said he expected that approval within the next few months. 
              &lt;p&gt; 
              &lt;p&gt;The current guidelines recommend periodic liver biopsies and cites a cumulative dose threshold of 1.5 g.
              &lt;p&gt; 
              &lt;p&gt;But in recent years several clinicians have questioned that threshold. 
              &lt;p&gt; 
              &lt;p&gt;Craig L. Leonardi, M.D., a dermatologist at Saint Louis University in St. Louis, said there was much controversy surrounding not only liver biopsies, but also the interpretation of the biopsy findings. 
              &lt;p&gt; 
              &lt;p&gt;He said he was &quot;trying to relax and wait until 3 g or 3.5 g before I&apos;m bothering my patients about liver biopsies.&quot;
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi said the issue was complicated by a subset of patients &quot;who are very tolerant of the drug.&quot; 
              &lt;p&gt; 
              &lt;p&gt;To illustrate, he described a patient who was referred to him who had a history of 25 mg of methotrexate a week for 20 years. He said the patient had been poorly managed with liver function tests only every other year and the patient also &quot;drank a couple of fingers of Scotch every night.&quot;
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi said when did a liver biopsy, the pathologist called to point out that the patient history must be incorrect because the liver was fine. 
              &lt;p&gt; 
              &lt;p&gt;Dr. Koo said he, too, had patients who appeared to be methotrexate tolerant, but he also had other patients who were in fulminant methotrexate-induced liver failure at relatively low doses. 
              &lt;p&gt; 
              &lt;p&gt;M. Shane Chapman, M.D., of Dartmouth-Hitchcock Medical Center in Lebanon, N.H., agreed that a guideline change was in order, but he said that if physicians believe that a patient may be harmed by methotrexate they should &quot;get the patient off the drug.&quot;
              &lt;p&gt; 
              &lt;p&gt;Henry H. Roenigk, Jr., M.D., professor emeritus at Northwestern, and chair of the SDEF psoriasis session, said methotrexate was the &quot;historic gold standard for psoriasis because it is so effective, with a 60% to 80% clear rate.&quot;
              &lt;p&gt; 
              &lt;p&gt;And, in the era of biologics that are noted for both their efficacy and price, &quot;methotrexate is cheap, and that&apos;s a key factor.&quot;
              &lt;p&gt; 
              &lt;p&gt;Dr. Roenigk noted, too, that rhematologists regularly use methotrexate &quot;with no biopsies.&quot; 
              &lt;p&gt; 
              &lt;p&gt;&lt;table cellspacing=&quot;0&quot; hspace=&quot;1&quot; style=&quot;border-style:solid; border-width:1px; border-color:#8dabbc; font-family:arial; font-size:12px; background-color:#DBE9F2; padding:5px 5px 5px 5px;&quot;&gt;
&lt;tr&gt;&lt;td&gt; Dr. Roenigk said he was on the speakers&apos; bureaus for Amgen, Genentech, and Abbott.
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi disclosed potential conflicts of interest with Abbott, Abgenix, Allergan, Amgen/Immunex, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Celgene, Centocor, Fujisawa, Genentech, Isis, and Medimmune.
              &lt;p&gt; 
              &lt;p&gt;Dr. Chapman disclosed potential conflicts of interest with Genentech, Centocor, and Abbott.
              &lt;p&gt; 
              &lt;p&gt;Dr. Koo disclosed potential conflicts of interest with Abbot, Amgen, Biogen, Bristol Meyers Squibb, Centacor, Connetics, Eisai, Fujisawa, Galderma, Genentech, Novartis, Serono, Teikoku, Valeant, and Warner-Chilcott.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
    </recommendedItem>
    <recommendedItem id="20090101_19_468"
                     title="SDEF: Newly Approved Vitamin D Ointment Appears Effective for Treatment of Plaque Psoriasis"
                     score="-0.005"
                     href="http://www.medpagetoday.com/MeetingCoverage/SDEF/tb/12887?impressionId=1265790496985"
                     
      WAILEA, Hawaii, Feb. 13 -- Three new topical treatments for psoriasis are now or soon will be available.
              &lt;p&gt; 
              &lt;p&gt;But only one of the three newcomers -- calcitriol (Vectical) is likely to gain widespread use, according to John Y.M. Koo, M.D., vice chairman of dermatology at the University of California San Francisco.
              &lt;p&gt; 
              &lt;p&gt;Dr. Koo reviewed three new topical psoriasis treatments -- calcitriol, Taclonex Scalp, and Hydrogel Patch -- during a psoriasis session at the Skin Disease Education Foundation (SDEF) Hawaii Dermatology Seminar. 
              &lt;p&gt; 
              &lt;p&gt;Calcitriol is a vitamin D ointment that was approved by the FDA earlier this month and is expected to be available in pharmacies by early spring, Dr. Koo said.
              &lt;p&gt; 
              &lt;p&gt;Taclonex Scalp (calcipotriene 0.005% and betamethasone dipropionate 0.064%), which was approved by the FDA in March 2008 for treatment of moderate to severe psoriasis vulgaris of the scalp, appears to be effective and could be used in combination with other topical or systemic therapies, he said.
              &lt;p&gt; 
              &lt;p&gt;Hydrogel Patch, an occlusion product, was also effective in clinical trials, but its use is limited by the FDA&apos;s decision &quot;to put a one-year expiration date on the product,&quot; Dr. Koo said.
              &lt;p&gt; 
              &lt;p&gt;Hydrogel Patch is made in Japan and &quot;by the time it arrives in the U.S. by ship, there is little time left before it expires. This product will only gain widespread use if the FDA grants it a two-year expiration date.&quot;
              &lt;p&gt; 
              &lt;p&gt;So, of the three new topical therapies, Dr. Koo said that calcitriol, in his opinion, was the one with the greatest potential for clinical utility.
              &lt;p&gt; 
              &lt;p&gt;In phase II trials of patients with mild-to-moderate plaque psoriasis treated twice daily for eight weeks, calcitriol was superior to vehicle with &quot;significant improvement at two weeks,&quot; he said.  Moreover, the benefit was sustained for eight weeks.
              &lt;p&gt; 
              &lt;p&gt;He said adverse events were minimal and generally mild, and calcitriol ointment &quot;did not show a clinical effect on calcium homeostasis.&quot;
              &lt;p&gt; 
              &lt;p&gt;In an open-label, 52-week study of 324 patients, the incidence of hypercalcemia was 3.1%, and did not differ regardless of body surface area affected, he said. 
              &lt;p&gt; 
              &lt;p&gt;After 52 weeks of twice daily treatment, &quot;64% of patients were marked &apos;improved&apos; compared with baseline,&quot; Dr. Koo said.
              &lt;p&gt; 
              &lt;p&gt;Clinically, Dr. Koo suggested that calcitriol will &quot;fit well in the sequential therapy of psoriasis -- in the quick fix or clearing phase it can be used with clobetasol, then used as monotherapy weekdays and in combination with clobetasol on weekends during the &apos;transitional phase&apos; of treatment, and finally as monotherapy during the maintenance phase.&quot;
              &lt;p&gt; 
              &lt;p&gt;&lt;table cellspacing=&quot;0&quot; hspace=&quot;1&quot; style=&quot;border-style:solid; border-width:1px; border-color:#8dabbc; font-family:arial; font-size:12px; background-color:#DBE9F2; padding:5px 5px 5px 5px;&quot;&gt;
&lt;tr&gt;&lt;td&gt;Dr. Koo disclosed potential conflicts of interest for Abbot. Amgen, Biogen, Bristol Meyers Squibb, Centacor, Connetics, Eisai, Fujisawa, Galderma, Genentech, Novartis, Serono, Teikoku, Valeant, and Warner-Chilcott.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
           
    </recommendedItem>
    <recommendedItem id="20090101_19_492"
                     title="SDEF: Investigational Biologics Highly Effective Against Plaque Psoriasis"
                     score="-0.005"
                     href="http://www.medpagetoday.com/MeetingCoverage/SDEF/tb/12915?impressionId=1265790496985"
                     
      WAILEA, Hawaii, Feb 16 -- Ustekinumab (Stelara), an investigational fully humanized monoclonal antibody that has been on hold awaiting FDA action for more than a year, is one of two investigational agents that may prove superior to available psoriasis treatments.
              &lt;p&gt; 
              &lt;p&gt;That was the conclusion of Craig L. Leonardi, M.D., a dermatologist at Saint Louis University in St. Louis, who reviewed findings from clinical trials of ustekinumab and ABT-874 at the Skin Disease Education Foundation Hawaii Dermatology Seminar.
              &lt;p&gt; 
              &lt;p&gt;The key to the potential superiority of both agents is that they target two interleukin molecules -- IL-12 and IL-23 -- a pair of critical cytokines in the promotion of psoriasis.
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi said phase III clinical trials of ustekinumab demonstrated efficacy at both 45 mg and 90 mg doses, which were administered at weeks 0, four and 12 as needed. 
              &lt;p&gt; 
              &lt;p&gt;The drug, which is given by subcutaneous injection and was submitted to FDA for approval in December 2007, has also demonstrated superiority for treatment in a head-to-head trial with etanercept (Enbrel), an inhibitor of tumor necrosis-alpha, reported last fall at the European Academy of Dermatology and Venereology meeting. (See: &lt;a href=&quot;http://www.medpagetoday.com/Dermatology/Psoriasis/10964&quot; target=&quot;blank&quot;&gt;EADV: Ustekinumab Outdoes Etanercept for Psoriasis&lt;/a&gt;)
              &lt;p&gt; 
              &lt;p&gt;Ustekinumab has also demonstrated efficacy for treatment of psoriatic arthritis. (See: &lt;a href=&quot;http://www.medpagetoday.com/Rheumatology/Arthritis/12884&quot; target=&quot;blank&quot;&gt;Psoriatic Arthritis Improves with Investigational Biologic&lt;/a&gt;) 
              &lt;p&gt; 
              &lt;p&gt;A major advantage of the drug, Dr. Leonardi said, is the fact that it works quickly and requires minimal injections. 
              &lt;p&gt; 
              &lt;p&gt;In the comparison with etanercept, the average number of ustekinumab injections was two, compared with an average of 23.1 for etanercept. 
              &lt;p&gt; 
              &lt;p&gt;Yet, at 12 weeks, 68% of patients treated with 45 mg of ustekinumab and 74% of those who received 90 mg of ustekinumab were cleared of at least 75% of psoriasis lesions (PASI 75) compared with only 57% of etanercept patients who achieved PASI 75 (&lt;em&gt;P&lt;/em&gt;=0.012 for 45 mg and P &lt;0.001 for 90 mg versus etanercept).
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi said that ABT-874, which is still conducting phase 3 trials, also works very fast. &quot;With just a single 200 mg dose, 63% of patients achieved PASI 75 at 12 weeks, and 93% of patients achieved PASI 75 with a 100 mg dose every other week for 12 weeks,&quot; he said.
              &lt;p&gt; 
              &lt;p&gt;If both investigational agents are approved by the FDA -- a prospect that Dr. Leonardi said appeared likely, but far from certain -- ustekinumab would join adalimumab (Humira) 40 mg every other week, and infliximab 5 mg every eight weeks as the most effective biologics for psoriasis.
              &lt;p&gt; 
              &lt;p&gt;Those would be followed by a group of &quot;moderate performers&quot; that Dr. Leonardi said included etanercept and efalizumab (Raptiva), followed by alefacept (Amevive). 
              &lt;p&gt; 
              &lt;p&gt; 
              &lt;p&gt;&lt;table cellspacing=&quot;0&quot; hspace=&quot;1&quot; style=&quot;border-style:solid; border-width:1px; border-color:#8dabbc; font-family:arial; font-size:12px; background-color:#DBE9F2; padding:5px 5px 5px 5px;&quot;&gt;
&lt;tr&gt;&lt;td&gt; Ustekinumab trials were funded by Centocor Inc., and trials of ABT-874 were funded by Abbott Laboratories.
              &lt;p&gt; 
              &lt;p&gt;Dr. Leonardi disclosed potential conflicts of interest with Abbott, Abgenix, Allergan, Amgen/Immunex, Biogen-IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Connetics, Corixa, Celgene, Centocor, Fujisawa, Genentech, Isis, and Medimmune.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
    </recommendedItem>
</recommendedContent>